Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
about
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewOptions for empagliflozin in combination therapy in type 2 diabetes mellitusDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsBridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive PotentialPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesDrug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.Empagliflozin in the treatment of type 2 diabetes: evidence to dateThe sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicityEffects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsIpragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.Short commentary on empagliflozin and its potential clinical impactThe role of empagliflozin in the management of type 2 diabetes by patient profile.Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 DiabetesClinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetesRenal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusSafety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialImpact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
P2860
Q24563917-7EDD3F33-FA35-4164-9412-A66D0EF60A31Q26745771-DD9E7570-38EA-4812-B425-E41B6206726AQ26749281-E00715EE-5939-4263-BC7B-DF55C4661FBBQ26864336-39512DC1-4A84-44BE-AF41-843015F233B7Q27027105-A57A4706-4F99-48F0-B3A6-042BAA9F3576Q28074843-B8AD7EE9-852F-479E-85DD-7F6E9D91B34FQ29994589-A7116218-52E7-4C00-9822-37E13AABE049Q30249371-725B4652-5996-4D20-BE72-44258F45ACCFQ33354192-F50567B9-854A-4D8E-AEA1-5E745ABE0277Q33607764-9AAC8317-DED7-40AA-A5F5-A05C67DABDFFQ33625568-F3DD6145-CEAB-4515-A4B9-1CACC1E02634Q33812170-DB7D43B2-A6B0-441E-BE0E-569B08F1B963Q33837017-7A9B5F77-9819-4CA7-B025-69E9656279AAQ33857698-291D386F-7440-480A-8C6B-948CA7A4220FQ34198692-CAFEC8E7-1B0F-4F17-BFF4-968794C174A4Q34397646-77B009D6-99AA-459C-8A3B-E7F294BD5AFDQ34502358-9EA625F5-3806-4A4D-BB65-DE2CCEF578EDQ34524690-16EC99D3-7426-4928-9F47-9B9AD2BA176AQ34579919-8D56741D-7DA7-4EF0-B71C-EB4FD3C6E599Q34973750-3CCC38F4-DA17-4975-B0E8-E4F89CBC7314Q35049845-2BD009FE-416C-4564-BBF0-F011A5F49DB5Q35117192-4C50D607-2D82-4FAC-AF2F-FCF4EBF9BE73Q35157497-CCE87599-CC8D-434B-B436-9CFBD6619AB6Q35528797-E0D3A5A6-2FDC-468C-BAC3-9A2944F09911Q35592873-21C374B6-A6D6-45D4-A739-F7A38E97AD96Q35669990-A2311B78-DADB-435B-AB0A-B2429CAF126BQ36221586-0A798EE4-1ED4-4757-8D89-0194695E7FCEQ36345951-FE8D2E15-5E88-4171-B767-FFF36EBD8D2EQ36402095-4E8FEA26-3F44-4CA3-9B3A-D77ABC779F13Q36555418-E9E573B3-31F2-44ED-B1EE-096DFE986D02Q36745809-6671C660-D03C-4585-B9E5-2F973C018E38Q36828139-48AB1429-E3D6-421F-9D2E-7568742728C8Q37278239-50926A59-115F-4DD7-8884-BA7EC073170FQ37279276-1A7F9492-1CA5-486F-8B97-A426869D93ADQ37325818-B94B0DDC-E6C1-4A95-9FBE-59825186EF45Q37331262-8D5FB163-1BFE-4A54-A2B2-9F50725F1784Q37351709-34B6B46D-4925-4B7A-B27D-CF906BD85EFAQ37468469-689EB2A5-51A4-4638-AFF9-3E9CBC44699FQ37575455-F033F4B5-7BAF-4112-B46C-6DE00E7A53C4Q37575461-DC8A7E74-9C72-4B01-8D93-E88F064945A7
P2860
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@ast
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@en
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@nl
type
label
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@ast
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@en
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@nl
prefLabel
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@ast
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@en
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@nl
P2093
P1476
Empagliflozin, a novel selecti ...... with other SGLT-2 inhibitors.
@en
P2093
F Himmelsbach
M Eckhardt
P Eickelmann
R A Bakker
R Grempler
P356
10.1111/J.1463-1326.2011.01517.X
P577
2011-11-13T00:00:00Z